Zacks.com on MSN6d
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
MeiraGTx Holdings’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD) ...
MeiraGTx announecs five posters at ESGCT 2024 Annual Congress
MeiraGTx (MGTX) announced the Company will exhibit five posters at the European Society of Gene and Cell Therapy, ESGCT, 2024 Annual Congress, ...
Zacks.com on MSN7d
MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?
MeiraGTx Holdings PLC (MGTX) shares ended the last trading session 14.9% higher at $5.33. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
MeiraGTx gains as gene therapy shows promise in Parkinson’s
MeiraGTx Holdings (MGTX) stock gains in premarket trading after positive trial results for the company's AAV-GAD gene therapy ...
MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings
Exciting results for MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease, with promising phase 1/2 data and ...
MeiraGTx Reports Positive AAV-GAD Trial Data For Parkinson's Disease; Stock Climbs
MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical-stage genetic medicines company, announced Tuesday positive top-line ...
bovnews7d
MeiraGTx Holdings PLC (MGTX) Stock: Greater Than Its Current Valuation?
On Tuesday, MeiraGTx Holdings PLC (MGTX) stock saw a modest uptick, ending the day at $5.33 which represents a slight increase of $0.69 or 14.87% from the prior close of $4.64. The stock opened at $5.
Nasdaq7d
MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?
MeiraGTx Holdings PLC (MGTX) shares ended the last trading session 14.9% higher at $5.33. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...